ストックスクリーナーアプリを入手
3.84
3.52%
-0.14
アフターアワーズ：
3.82
-0.02
-0.52%
Femasys Inc (FEMY) 最新ニュース
FEMY Stock Price, Quote & Chart - ChartMill
FEMY Q1 2026 Earnings: EPS Surprises to the Upside as Narrower Loss Drives Stock HigherBalance Sheet Strength - newsline.com
Femasys Inc. (FEMY) Edges Higher as Stock Tests Key Resistance LevelsWMA Signal - newsline.com
Femasys, Inc. Hits New 52-Week Low at $5.08 Amid Market Challenges - MarketsMojo
Femasys Inc. (FEMY) Q1 2026 Earnings: EPS Surprises to the Upside Despite Stock DeclineEstimate Dispersion - newsline.com
Femasys Inc. (FEMY) Shares Decline 14% as Price Tests Support Near $0.29Dark Pool Prints - newsline.com
Femasys Announces 1-for-20 Reverse Stock Split Implementation - TipRanks
Femasys (NASDAQ: FEMY) implements 1-for-20 reverse stock split - Stock Titan
Femasys (FEMY) Slides 2.96% as Shares Test Key Support LevelVolume Spike Alerts - newsline.com
Femasys Announces 1-for-20 Reverse Stock Split Initiative - TipRanks
Femasys to implement 1-for-20 reverse stock split; trading symbol FEMY unchanged - TradingView
Reverse split will consolidate Femasys (NASDAQ: FEMY) common shares 20-to-1 - Stock Titan
Femasys, Inc. Financial Disclosures & SEC Filings - TradingView
Femasys Inc. (FEMY) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Revenue UncertaintyRevenue Growth Report - newsline.com
FEMY Technical Analysis & Stock Price Forecast - Intellectia AI
Femasys Inc. (FEMY) Edges Higher as Key Support Holds at $0.37Technical Analysis Picks - The Legal Advocate
Femasys Inc. (FEMY) Edges Higher: Navigating Key Support and Resistance LevelsCumulative Volume - newsline.com
Femasys Inc. (FEMY) Q1 2026 Earnings: EPS Beat Drives 29.85% Stock SurgeMid-Term Outlook - newsline.com
Femasys Analyst Ratings and Price Targets | NASDAQ:FEMY - Benzinga
Femasys Jumps Almost 30% as Nasdaq Deadline Remains - TechStock²
FEMY Technical Analysis | Trend, Signals & Chart Patterns | FEMASYS INC (NASDAQ:FEMY) - ChartMill
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter - Sahm
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and Protara Therapeutics (TARA) - The Globe and Mail
Femasys receives CE Mark approval for FemHSG fertility catheter - Investing.com UK
Femasys updates corporate presentation on women’s health portfolio - TipRanks
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
Femasys posts updated corporate presentation detailing fertility and FemBloc commercialization plans - TradingView
Femasys (NASDAQ: FEMY) outlines FemaSeed fertility and FemBloc birth control strategy - Stock Titan
Femasys receives CE Mark approval for FemHSG fertility catheter By Investing.com - Investing.com South Africa
Lake Street Remains a Buy on Femasys (FEMY) - The Globe and Mail
Femasys Expands Fertility Care Portfolio In Europe With CE Mark Approval For Femhsg™ Catheter - TradingView
TradingKey - TradingKey
Femasys Reverse Stock Split May Not Prevent Nasdaq Delisting Risk, Observer Warns - The Globe and Mail
Femasys Inc. Announces Financial Results for Quarter Ending March 31, 2026 - geneonline.com
Femasys Inc. Q1 2026 Financials: Revenue Growth, Forward-Looking Statements, and Market Strategy - Minichart
Femasys Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
FEMASYS INC 1Q 2026: Revenue $424.9K, Net income $328.6K, EPS $0— 10-Q Summary - TradingView
Non-cash gains lift Femasys (NASDAQ: FEMY) to Q1 profit amid cash strain - Stock Titan
Net income returns at Femasys (NASDAQ: FEMY) as Q1 2026 results filed - Stock Titan
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - The Manila Times
Femasys starts birth-control trial as it expands fertility care - Stock Titan
Press Release: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - Moomoo
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
FEMY | Femasys Inc. Common Stock Insider Trading - Quiver Quantitative
How Femasys (FEMY) maintains its asset base | Q4 2025: Better Than ExpectedWeak Earnings Momentum - newsline.com
Why Femasys (FEMY) valuation makes sense when you dig deeper (Steady Decline) 2026-05-07Earnings Beat Stocks - The Legal Advocate
Femasys pushes fertility treatment into OB/GYN offices with first paid use - Stock Titan
Femasys Enables OB/GYNs to Deliver First-Line Fertility - GlobeNewswire
MSN Money - MSN
The inflation impact visible in Femasys (FEMY) results | Q4 2025: EPS Tops ViewsEPS Guidance Update - newsline.com
FEMY Earnings History & Surprises | EPS & Revenue Results | FEMASYS INC (NASDAQ:FEMY) - ChartMill
Femasys Shareholders Approve Reverse Split and Financing Plans - The Globe and Mail
Femasys Inc. (NASDAQ: FEMY) sets 2026 meeting, director and auditor votes - Stock Titan
[ARS] FEMASYS INC SEC Filing - Stock Titan
1.68%
0.71%
大文字化:
|
ボリューム (24 時間):